Growth Factor News and Research

RSS

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.

15 Sep 2014

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Oraya Therapeutics Inc. announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone.

15 Sep 2014

Professor receives award for development of anti-angiogenic therapy for retinal disease

Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal.

11 Sep 2014

Growth factors present in human breast milk may protect against intestinal damage

Studies Suggest that ErbB4 Receptor Activation May Be a Novel Therapeutic Avenue for Intestinal Diseases Involving Epithelial Cell Death, According to Research Published in The American Journal of Pathology

10 Sep 2014

Transplantation of B10 cells helps inhibit development of bladder fibrosis post SCI

A team of researchers from Korea and Canada have found that transplantation of B10 cells (a stable immortalized human bone marrow derived -mesenchymal stem cell line; B10 hMSC) directly into the bladder wall of mice modeled with spinal cord injury (SCI) helped inhibit the development of bladder fibrosis and improved bladder function by promoting the growth of smooth muscle cells in the bladder.

4 Sep 2014

Using molecular imaging probes diabetic retinopathy can be detected at molecular level

A new study published in the September issue of The FASEB Journal, identifies a novel strategy to diagnose the leading cause of blindness in adults, diabetic retinopathy, before irreversible structural damage has occurred.

3 Sep 2014

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly.

2 Sep 2014

Study compares FK506 and rapamycin for Schwann cell migration, peripheral nerve regeneration

FK506 possesses a well-studied neuroregenerative effect, stimulating neurite extension in the presence of nerve growth factor in vitro, and enhancing nerve regeneration following nerve crush injury and isografting.

30 Aug 2014

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

28 Aug 2014

Mutant allele frequency predicts lung cancer TKI response

Tyrosine kinase inhibitor sensitivity may be predicted by the frequency of a point mutation in the epidermal growth factor receptor gene, suggests a study of Japanese patients with advanced lung adenocarcinoma.

28 Aug 2014

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.

28 Aug 2014

Reticular pseudodrusen predicts late-stage AMD

Reticular pseudodrusen increases the likelihood of people with choroidal neovascularisation in one eye also developing late-stage, age-related macular degeneration in the other eye, researchers report.

28 Aug 2014

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly is a chronic, life-threatening disease triggered by a benign tumour of the pituitary gland causing excessive growth hormone release. Oversupply of growth hormone stimulates liver, fat and kidney cells to produce excess levels of Insulin-Like Growth Factor I (IGFI), which causes abnormal growth of the bones of the hands, face and feet and bodily organs.

26 Aug 2014

Researchers find why certain glioblastomas become drug resistance

Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas - the primary form of a deadly brain cancer - are resistant to drug therapy.

26 Aug 2014

Researchers examine impact of BIM deletion on survival outcomes of advanced NSCLC patients

Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients.

25 Aug 2014

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib is a valid treatment option for patients with KRAS wild-type lung adenocarcinoma refractory to chemotherapy, study data show.

21 Aug 2014

EGFR biomarkers predict NSCLC response to vandetanib

Biomarker analyses of tumour samples from the ZODIAC study indicate that epidermal growth factor receptor gene copy number and mutation status may help identify the non-small-cell lung cancer patients most likely to benefit from treatment with vandetanib plus docetaxel.

20 Aug 2014

Choroidal consequences differ between anti-VEGF therapies

Aflibercept’s possession of a fragment crystallisable region may make it more likely to induce unwanted effects in retinal and choroidal vessels than other anti-vascular endothelial growth factor therapies, say researchers.

20 Aug 2014

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista Pharmaceuticals, an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME.

20 Aug 2014

Chemical engineers devise new implantable tissue scaffold coated with bone growth factors

MIT chemical engineers have devised a new implantable tissue scaffold coated with bone growth factors that are released slowly over a few weeks. When applied to bone injuries or defects, this coated scaffold induces the body to rapidly form new bone that looks and behaves just like the original tissue.

20 Aug 2014

Growth Factor News and Research

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Professor receives award for development of anti-angiogenic therapy for retinal disease

Growth factors present in human breast milk may protect against intestinal damage

Transplantation of B10 cells helps inhibit development of bladder fibrosis post SCI

Using molecular imaging probes diabetic retinopathy can be detected at molecular level

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Study compares FK506 and rapamycin for Schwann cell migration, peripheral nerve regeneration

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Mutant allele frequency predicts lung cancer TKI response

High PD-L1 expression linked to reduced survival in NSCLC

Reticular pseudodrusen predicts late-stage AMD

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Researchers find why certain glioblastomas become drug resistance

Researchers examine impact of BIM deletion on survival outcomes of advanced NSCLC patients

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

EGFR biomarkers predict NSCLC response to vandetanib

Choroidal consequences differ between anti-VEGF therapies

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

Chemical engineers devise new implantable tissue scaffold coated with bone growth factors

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News